Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes

Endocrine-Related Cancer

Volumn 17, Issue 4, 2010, Pages 941-951

  Fierz, Yvonne ^a   Novosyadlyy, Ruslan ^a   Vijayakumar, Archana ^a   Yakar, Shoshana ^a   LeRoith, Derek ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HYPERINSULINEMIA; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN FUNCTION; TRANSGENIC MOUSE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLOOD GLUCOSE; BODY WEIGHT; BREAST NEOPLASMS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; EATING; FEMALE; INSULIN; MICE; MICE, TRANSGENIC; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRIGLYCERIDES;

EID: 78649816080     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-10-0091     Document Type: Article

References (47)

1. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC & Brancati FL 2008 Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. Journal of the American Medical Association 300 2754-2764. (doi:10.1001/jama.2008.824)
2. Bellmunt J, Szczylik C, Feingold J, Strahs A & Berkenblit A 2008 Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Annals of Oncology 19 1387-1392. (doi:10.1093/annonc/mdn066)
3. Blouet C, Ono H & Schwartz GJ 2008 Mediobasal hypothalamic p70 S6 kinase 1 modulates the control of energy homeostasis. Cell Metabolism 8 459-467. (doi:10. 1016/j.cmet.2008.10.004)
4. Borowsky AD, Namba R, Young LJ, Hunter KW, Hodgson JG, Tepper CG, McGoldrick ET, Muller WJ, Cardiff RD & Gregg JP 2005 Syngeneic mouse mammary carcinoma cell lines: two closely related cell lines with divergent metastatic behavior. Clinical & Experimental Metastasis 22 47-59. (doi:10.1007/s10585- 005-2908-5)
5. Campbell MJ, Wollish WS, Lobo M & Esserman LJ 2002 Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse. In Vitro Cellular & Developmental Biology. Animal 38 326-333. (doi:10.1290/1071-2690(2002)038〈0326:EAFCLD〉2.0.CO;2)
6. Chang GR, Chiu YS, Wu YY, Chen WY, Liao JW, Chao TH & Mao FC 2009a Rapamycin protects against high fat diet-induced obesity in C57BL/6J mice. Journal of Pharmacological Sciences 109 496-503. (doi:10.1254/ jphs.08215FP)
7. Chang GR, Wu YY, Chiu YS, Chen WY, Liao JW, Hsu HM, Chao TH, Hung SW & Mao FC 2009b Long-term administration of rapamycin reduces adiposity, but impairs glucose tolerance in high-fat diet-fed KK/HlJ mice. Basic Clinical Pharmacology & Toxicology 105 188-198. (doi:10.1111/j.1742-7843.2009.00427. x)
8. Cowan PA & Heizer KE 2000 Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection. Nephrology Nursing Journal 27 623-625.
9. Dancey JE, Curiel R & Purvis J 2009 Evaluating temsirolimus activity in multiple tumors: a review of clinical trials. Seminars in Oncology 36 (Supplement 3) S46-S58. (doi:10.1053/j.seminoncol.2009.10.010)
10. Fernandez AM, Kim JK, Yakar S, Dupont J, Hernandez- Sanchez C, Castle AL, Filmore J, Shulman GI & LeRoith D 2001 Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes and Development 15 1926-1934. (doi:10.1101/gad.908001)
11. Fierz Y, Novosyadlyy R, Vijayakumar A, Yakar S & LeRoith D 2010 Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Diabetes 59 686-693. (doi:10.2337/db09-1291)
12. Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, Castel J, Berthault MF, Magnan C, Cerasi E, Kaiser N et al. 2008 mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 57 945-957. (doi:10.2337/db07-0922)
13. Guertin DA & Sabatini DM 2007 Defining the role of mTOR in cancer. Cancer Cell 12 9-22. (doi:10.1016/j.ccr.2007. 05.008)
14. Guy CT, Cardiff RD & Muller WJ 1992 Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Molecular and Cellular Biology 12 954-961.
15. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR et al. 2004 The TSC1-2 tumor suppressor control insulin - PI3K signaling via regulation of IRS proteins. Journal of Cell Biology 166 213-223. (doi:10.1083/jcb. 200403069)
16. Heitman J, Movva NR & Hall MN 1991 Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 23 905-909. (doi:10.1126/science.1715094)
17. Hynes NE & Boulay A 2006 The mTOR pathway in breast cancer. Journal of Mammary Gland Biology and Neoplasia 11 53-61. (doi:10.1007/s10911-006-9012-6)
18. Johnston O, Rose CL, Webster AC & Gill JS 2008 Sirolimus is associated with new-onset diabetes in kidney transplant recipients. Journal of the American Society of Nephrology 19 1411-1418. (doi:10.1681/ASN.2007111202)
19. Lann D & LeRoith D 2008 The role of endocrine insulin-like growth factor-I and insulin in breast cancer. Journal of Mammary Gland Biology and Neoplasia 13 371-379. (doi:10.1007/s10911-008-9100-x)
20. Larsson SC, Mantzoros CS & Wolk A 2007 Diabetes mellitus and risk of breast cancer: a meta-analysis. International Journal of Cancer 121 856-862. (doi:10.1002/ijc.22717) (Pubitemid 47106217)
21. Li J, DeFea K & Roth RA 1999 Modulation of insulin receptor substrate-1 tyrosine phosphorylation by an Akt/phosphatidylinositol 3-kinase pathway. Journal of Biological Chemistry 274 9351-9356. (doi:10.1074/jbc. 274.14.9351)
22. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ & Pollard JW 2003 Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. American Journal of Pathology 163 2113-2126.
23. Liu M, Howes A, Lesperance J, Stallcup WB, Hauser CA, Kadoya K, Oshima RG & Abraham RT 2005 Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. Cancer Research 65 5325-5336. (doi:10.1158/0008-5472. CAN-04-4589)
24. Malizzia LJ & Hsu A 2008 Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma. Clinical Journal of Oncology Nursing 12 639-646. (doi:10.1188/08.CJON.639-646)
25. Manning BD & Cantley LC 2007 AKT/PKB signaling: navigating downstream. Cell 129 1261-1274. (doi:10.1016/ j.cell.2007.06.009)
26. Meier-Kriesche HU & Kaplan B 2000 Toxicity and efficacy of sirolimus: relationship to whole-blood concentrations. Clinical Therapeutics 22 B93-100. (doi:10.1016/S0149-2918(00)89026-8)
27. Morrisett JD, Abdel-Fattah G & Kahan BD 2003 Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplantation Proceedings 35 143S-150S. (doi:10.1016/S0041-1345(03)00233-1)
28. Mosley JD, Poirier JT, Seachrist DD, Landis MD & Keri RA 2007 Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer. Molecular Cancer Therapeutics 6 2188-2197. (doi:10.1158/1535-7163. MCT-07-0235)
29. Namba R, Young LJ, Abbey CK, Kim L, Damonte P, Borowsky AD, Qi J, Tepper CG, MacLeod CL, Cardiff RD et al. 2006 Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Clinical Cancer Research 12 2613-2621. (doi:10.1158/1078-0432.CCR-05-2170)
30. Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, Mills GB, Hung MC & Meric-Bernstam F 2004 Determinants of rapamycin sensitivity in breast cancer cells. Clinical Cancer Research 10 1013-1023. (doi:10. 1158/1078-0432.CCR-03-0043)
31. Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y, Carboni JM, Gottardis MM, Pennisi PA, Molinolo AA et al. 2010a Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Research 70 741-751. (doi:10.1158/0008-5472. CAN-09-2141)
32. Novosyadlyy R, Vijayakumar A, Fierz Y & LeRoith D 2010b Animal models of hyperinsulinemia, insulin resistance and cancer. Ed IG Fantus. New York, NY, USA: Springer.
33. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL et al. 2006 mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Research 66 1500-1508. (doi:10.1158/0008-5472.CAN-05-2925)
34. Pende M, Kozma SC, Jaquet M, Oorschot V, Burcelin R, Le Marchand-Brustel Y, Klumperman J, Thorens B & Thomas G 2000 Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature 408 994-997. (doi:10.1038/35050135)
35. Phung TL, Eyiah-Mensah G, O'Donnell RK, Bieniek R, Shechter S, Walsh K, Kuperwasser C & Benjamin LE 2007 Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression. Cancer Research 67 5070-5075. (doi:10.1158/ 0008-5472.CAN-06-3341)
36. Rachdi L, Balcazar N, Osorio-Duque F, Elghazi L, Weiss A, Gould A, Chang-Chen KJ, Gambello MJ & Bernal-Mizrachi E 2008 Disruption of Tsc2 in pancreatic beta cells induces beta cell mass expansion and improved glucose tolerance in a TORC1-dependent manner. PNAS 105 9250-9255. (doi:10.1073/ pnas.0803047105)
37. Sarbassov DD, Guertin DA, Ali SM & Sabatini DM 2005 Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 1098-1101. (doi:10.1126/science.1106148)
38. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL & Sabatini DM 2006 Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Molecular Cell 22 159-168. (doi:10.1016/j.molcel.2006.03.029)
39. Teutonico A, Schena PF & Di Paolo S 2005 Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. Journal of the American Society of Nephrology 16 3128-3135. (doi:10.1681/ASN. 2005050487)
40. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J et al. 2004 Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431 200-205. (doi:10.1038/ nature02866)
41. Veilleux A, Houde VP, Bellmann K & Marette A 2010 Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes. Molecular Endocrinology 24 766-778. (doi:10.1210/me.2009-0328)
42. Vézina C, Kudelski A & Sehgal SN 1975 Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. Journal of Antibiotics 28 721-726.
43. Vona-Davis L, Howard-McNatt M&Rose DP 2007 A diposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obesity Reviews 8 395-408. (doi:10.1111/j.1467-789X. 2007.00396.x)
44. Wullschleger S, Loewith R & Hall MN 2006 TOR signaling in growth and metabolism. Cell 10 471-484. (doi:10. 1016/j.cell.2006.01.016)
45. Xue F & Michels KB 2007 Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. American Journal of Clinical Nutrition 86 s823-s835.
46. Yang CH, Chuang CK, Hsieh JJ & Chang JW 2010 Targeted therapy and hand - foot skin reaction in advanced renal cell carcinoma. Expert Opinion on Drug Safety 9 459-470. (doi:10.1517/14740331003596349)
47. Zahr E, Molano RD, Pileggi A, Ichii H, Jose SS, Bocca N, An W, Gonzalez-Quintana J, Fraker C, Ricordi C et al. 2007 Rapamycin impairs in vivo proliferation of islet beta cells. Transplantation 84 1576-1583. (doi:10.1097/01.tp.0000296035.48728.28)